Enhertu with Perjeta nearly doubled progression-free survival versus standard treatment in metastatic HER2-positive breast cancer, study shows.

Mwende was diagnosed with stage 0 breast cancer during a routine check-up. She had no family history, no warning signs. She ...

Envision this possible future clinical scenario: a breast cancer patient and her physicians are deciding on the best possible ...

College of Pharmacy, Touro University, 1310 Johnson Lane, Mare Island, Vallejo, California 94592, and Buck Institute for Age Research, 8001 Redwood Boulevard, Novato, California 94945 * To whom ...

Trastuzumab deruxtecan plus pertuzumab demonstrated statistically and clinically significant improvement in progression-free ...

Researchers at ASCO's annual meeting also discussed the importance of repeat biopsies to assess HER2 status after first-line ...

A clinical trial at MSK found that music therapy for cancer-related anxiety is as effective as cognitive behavioral therapy and produces long-lasting benefits. Dr. Kevin Liou presented the results of ...

AstraZeneca and Daiichi Sankyo’s drug extended survival by 30% compared to a widely used regimen, further establishing its ...

such as chemotherapy and targeted therapy, were treated with DB-1310. Among these patients, 108 had NSCLC, 62 of whom had EGFR-mutant NSCLC, and 24 were patients with brain metastases. In the ...

Jiang Su Key Laboratory of Drug Design and Optimization and Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing 210009, China Jiang Su Key Laboratory of ...

Despite significant advances in understanding the occurrence, progression and treatment of chronic lymphocytic leukemia (CLL), there remains a need to explore novel mechanisms and therapeutic ...